Citations

Clear

3030 citation(s) found for "Susan, M".

Management of Congenital Long-QT Syndrome: Commentary From the Experts
Kaufman, Elizabeth S. , Eckhardt, Lee L. , Ackerman, Michael J. , Aziz, Peter F. , Behr, Elijah R. , Cerrone, Marina , Chung, Mina K. , Cutler, Michael J. , Etheridge, Susan P. , Krahn, Andrew D. , Lubitz, Steven A. , Priori, Silvia G. , Roberts, Jason D. , Roden, Dan M. , Schulze‐Bahr, Eric , Shoemaker, M. Benjamin , Sy, Raymond W. , Towbin, Jeffrey A. , Wilde, Arthur A.M. , Zaręba, Wojciech , Behr, Elijah Raphael , Eckhardt, Lee L , Krahn, Andrew D , Lubitz, Steven A , Cerrone, Marina , Zareba, Wojciech , Priori, Silvia , Pérez, Marco , Roden, Dan M. , Schwartz, Peter J. , Shimizu, Wataru , Viskin, Sami

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | July 9, 2021 | Volume: 14 | Issue: 7 | Pages: No page available

10.1161/circep.120.009726 | PMID 34238011 Get It

While published guidelines are useful in the care of patients with long-QT syndrome, it can be difficult to decide how to apply the guidelines to individual patients, particularly those with intermediate risk. We explored the diversity of opinion among 24 clinicians with expertise in long-QT syndrome. Experts from various regions and institutions were presented with 4 challenging clinical scenarios and asked to provide commentary emphasizing why they would make their treatment recommendations. All 24 authors were asked to vote on case-specific questions so as to demonstrate the degree of consensus or divergence of opinion. Of 24 authors, 23 voted and 1 abstained. Details of voting results with commentary are presented. There was consensus on several key points, particularly on the importance of the diagnostic evaluation and of β-blocker use. There was diversity of opinion about the appropriate use of other therapeutic measures in intermediate-risk individuals. Significant gaps in knowledge were identified.
2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Polyarteritis Nodosa
Gorelik, Mark , Langford, Carol A. , Maz, Mehrdad , Abril, Andy , Archer, Amy M., Conn, Doyt L. , Full, Kathy A., Grayson, Peter C. , Ibarra, Maria, Imundo, Lisa F., Kim, Susan , Rhee, Rennie L. , Stone, John H. , Sule, Sangeeta , Vitobaldi, Omar I., Warner, Ann, Byram, Kevin , Dua, Anisha B. , Husainat, Nedaa , James, Karen , Kalot, Mohamad A. , Lin, Yih Chang, Springer, Jason , Turgunbaev, Marat, Villa‐Forte, Alexandra, Turner, Amy S. , Maz, Mehrdad , Conn, Doyt L , Grayson, Peter C , Merkel, Peter A , Rhee, Rennie L , Stone, John H , Sule, Sangeeta , Husainat, Nedaa M , Kalot, Mohamad A , Springer, Jason M , Turner, Amy S , Mustafa, Reem A , Dua, Anisha B , Chung, Sharon A. , Guyatt, Gordon , Merkel, Peter A. , Seo, Philip , Sundel, Robert P. , Warner, Ann

Mayo Clinic

Arthritis Care & Research | July 8, 2021 | Volume: 73 | Issue: 8 | Pages: 1061-1070

10.1002/acr.24633 | PMID 34235889 Get It

Objective To provide evidence‐based recommendations and expert guidance for the management of systemic polyarteritis nodosa (PAN). Methods Twenty‐one clinical questions regarding diagnostic testing, treatment, and management were developed in the population, intervention, comparator, and outcome (PICO) format for systemic, non–hepatitis B–related PAN. Systematic literature reviews were conducted for each PICO question. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to assess the quality of evidence and formulate recommendations. Each recommendation required ≥70% consensus among the Voting Panel. Results We present 16 recommendations and 1 ungraded position statement for PAN. Most recommendations were graded as conditional due to the paucity of evidence. These recommendations support early treatment of severe PAN with cyclophosphamide and glucocorticoids, limiting toxicity through minimizing long‐term exposure to both treatments, and the use of imaging and tissue biopsy for disease diagnosis. These recommendations endorse minimizing risk to the patient by using established therapy at disease onset and identify new areas where adjunctive therapy may be warranted. Conclusion These recommendations provide guidance regarding diagnostic strategies, use of pharmacologic agents, and imaging for patients with PAN.
2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis
Maz, Mehrdad , Abril, Andy , Langford, Carol A. , Gorelik, Mark , Archer, Amy M., Conn, Doyt L. , Full, Kathy A., Grayson, Peter C. , Ibarra, Maria, Imundo, Lisa F., Kim, Susan , Rhee, Rennie L. , Stone, John H. , Sule, Sangeeta , Vitobaldi, Omar I., Warner, Ann, Byram, Kevin , Dua, Anisha B. , Husainat, Nedaa , Kalot, Mohamad A. , Lin, Yih Chang, Springer, Jason , Turgunbaev, Marat, Villa‐Forte, Alexandra, Turner, Amy S. , Conn, Doyt L , Grayson, Peter C , Merkel, Peter A , Rhee, Rennie L , Stone, John H , Sule, Sangeeta , Husainat, Nedaa M , Kalot, Mohamad A , Springer, Jason M , Turner, Amy S , Mustafa, Reem A , Maz, Mehrdad , Dua, Anisha B , Chung, Sharon A. , Guyatt, Gordon , Merkel, Peter A. , Seo, Philip , Sundel, Robert P. , Warner, Ann, James, Karen E.

Mayo Clinic

Arthritis Care & Research | July 8, 2021 | Volume: 73 | Issue: 8 | Pages: 1071-1087

10.1002/acr.24632 | PMID 34235871 Get It

Objective To provide evidence‐based recommendations and expert guidance for the management of giant cell arteritis (GCA) and Takayasu arteritis (TAK) as exemplars of large vessel vasculitis. Methods Clinical questions regarding diagnostic testing, treatment, and management were developed in the population, intervention, comparator, and outcome (PICO) format for GCA and TAK (27 for GCA, 27 for TAK). Systematic literature reviews were conducted for each PICO question. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to rate the quality of the evidence. Recommendations were developed by the Voting Panel, comprising adult and pediatric rheumatologists and patients. Each recommendation required ≥70% consensus among the Voting Panel. Results We present 22 recommendations and 2 ungraded position statements for GCA, and 20 recommendations and 1 ungraded position statement for TAK. These recommendations and statements address clinical questions relating to the use of diagnostic testing, including imaging, treatments, and surgical interventions in GCA and TAK. Recommendations for GCA include support for the use of glucocorticoid‐sparing immunosuppressive agents and the use of imaging to identify large vessel involvement. Recommendations for TAK include the use of nonglucocorticoid immunosuppressive agents with glucocorticoids as initial therapy. There were only 2 strong recommendations; the remaining recommendations were conditional due to the low quality of evidence available for most PICO questions. Conclusion These recommendations provide guidance regarding the evaluation and management of patients with GCA and TAK, including diagnostic strategies, use of pharmacologic agents, and surgical interventions.
2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Polyarteritis Nodosa
Gorelik, Mark , Langford, Carol A. , Maz, Mehrdad , Abril, Andy , Archer, Amy M., Conn, Doyt L. , Full, Kathy A., Grayson, Peter C. , Ibarra, Maria, Imundo, Lisa F., Kim, Susan , Rhee, Rennie L. , Stone, John H. , Sule, Sangeeta , Vitobaldi, Omar I., Warner, Ann, Byram, Kevin , Husainat, Nedaa , Kalot, Mohamad A. , Lin, Yih Chang, Springer, Jason , Turgunbaev, Marat, Villa‐Forte, Alexandra, Turner, Amy S. , Maz, Mehrdad , Conn, Doyt L , Grayson, Peter C , Merkel, Peter A , Rhee, Rennie L , Stone, John H , Sule, Sangeeta , Husainat, Nedaa M , Kalot, Mohamad A , Springer, Jason M , Turner, Amy S , Mustafa, Reem A , Chung, Sharon A. , Guyatt, Gordon , Merkel, Peter A. , Seo, Philip , Sundel, Robert P. , Warner, Ann, Dua, Anisha B. , James, Karen E.

Mayo Clinic

Arthritis & Rheumatology | July 8, 2021 | Volume: 73 | Issue: 8 | Pages: 1384-1393

10.1002/art.41776 | PMID 34235883 Get It

Objective To provide evidence‐based recommendations and expert guidance for the management of systemic polyarteritis nodosa (PAN). Methods Twenty‐one clinical questions regarding diagnostic testing, treatment, and management were developed in the population, intervention, comparator, and outcome (PICO) format for systemic, non–hepatitis B–related PAN. Systematic literature reviews were conducted for each PICO question. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to assess the quality of evidence and formulate recommendations. Each recommendation required ≥70% consensus among the Voting Panel. Results We present 16 recommendations and 1 ungraded position statement for PAN. Most recommendations were graded as conditional due to the paucity of evidence. These recommendations support early treatment of severe PAN with cyclophosphamide and glucocorticoids, limiting toxicity through minimizing long‐term exposure to both treatments, and the use of imaging and tissue biopsy for disease diagnosis. These recommendations endorse minimizing risk to the patient by using established therapy at disease onset and identify new areas where adjunctive therapy may be warranted. Conclusion These recommendations provide guidance regarding diagnostic strategies, use of pharmacologic agents, and imaging for patients with PAN.
2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
Langford, Carol A. , Maz, Mehrdad , Abril, Andy , Gorelik, Mark , Archer, Amy M., Conn, Doyt L. , Full, Kathy A., Grayson, Peter C. , Ibarra, Maria, Imundo, Lisa F., Kim, Susan , Rhee, Rennie L. , Stone, John H. , Sule, Sangeeta , Vitobaldi, Omar I., Warner, Ann, Byram, Kevin , Husainat, Nedaa , Kalot, Mohamad A. , Lin, Yih Chang, Springer, Jason , Turgunbaev, Marat, Villa‐Forte, Alexandra, Turner, Amy S. , Maz, Mehrdad , Conn, Doyt L , Grayson, Peter C , Merkel, Peter A , Rhee, Rennie L , Stone, John H , Sule, Sangeeta , Husainat, Nedaa M , Kalot, Mohamad A , Springer, Jason M , Turner, Amy S , Mustafa, Reem A , Chung, Sharon A. , Guyatt, Gordon , Merkel, Peter A. , Seo, Philip , Sundel, Robert P. , Warner, Ann, Dua, Anisha B. , James, Karen E.

Mayo Clinic

Arthritis Care & Research | July 8, 2021 | Volume: 73 | Issue: 8 | Pages: 1088-1105

10.1002/acr.24634 | PMID 34235880 Get It

Objective To provide evidence‐based recommendations and expert guidance for the management of antineutrophil cytoplasmic antibody–associated vasculitis (AAV), including granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). Methods Clinical questions regarding the treatment and management of AAV were developed in the population, intervention, comparator, and outcome (PICO) format (47 for GPA/MPA, 34 for EGPA). Systematic literature reviews were conducted for each PICO question. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to assess the quality of evidence and formulate recommendations. Each recommendation required ≥70% consensus among the Voting Panel. Results We present 26 recommendations and 5 ungraded position statements for GPA/MPA, and 15 recommendations and 5 ungraded position statements for EGPA. This guideline provides recommendations for remission induction and maintenance therapy as well as adjunctive treatment strategies in GPA, MPA, and EGPA. These recommendations include the use of rituximab for remission induction and maintenance in severe GPA and MPA and the use of mepolizumab in nonsevere EGPA. All recommendations are conditional due in part to the lack of multiple randomized controlled trials and/or low‐quality evidence supporting the recommendations. Conclusion This guideline presents the first recommendations endorsed by the American College of Rheumatology and the Vasculitis Foundation for the management of AAV and provides guidance to health care professionals on how to treat these diseases.
2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis
Maz, Mehrdad , Abril, Andy , Langford, Carol A. , Gorelik, Mark , Archer, Amy M., Conn, Doyt L. , Full, Kathy A., Grayson, Peter C. , Ibarra, Maria, Imundo, Lisa F., Kim, Susan , Rhee, Rennie L. , Stone, John H. , Sule, Sangeeta , Vitobaldi, Omar I., Warner, Ann, Byram, Kevin , Dua, Anisha B. , Husainat, Nedaa , James, Karen , Kalot, Mohamad A. , Lin, Yih Chang, Springer, Jason , Turgunbaev, Marat, Villa‐Forte, Alexandra, Turner, Amy S. , Conn, Doyt L , Grayson, Peter C , Merkel, Peter A , Rhee, Rennie L , Stone, John H , Sule, Sangeeta , Husainat, Nedaa M , Kalot, Mohamad A , Springer, Jason M , Turner, Amy S , Mustafa, Reem A , Maz, Mehrdad , Dua, Anisha B , Chung, Sharon A. , Guyatt, Gordon , Merkel, Peter A. , Seo, Philip , Sundel, Robert P. , Warner, Ann

Mayo Clinic

Arthritis & Rheumatology | July 8, 2021 | Volume: 73 | Issue: 8 | Pages: 1349-1365

10.1002/art.41774 | PMID 34235884 Get It

Objective To provide evidence‐based recommendations and expert guidance for the management of giant cell arteritis (GCA) and Takayasu arteritis (TAK) as exemplars of large vessel vasculitis. Methods Clinical questions regarding diagnostic testing, treatment, and management were developed in the population, intervention, comparator, and outcome (PICO) format for GCA and TAK (27 for GCA, 27 for TAK). Systematic literature reviews were conducted for each PICO question. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to rate the quality of the evidence. Recommendations were developed by the Voting Panel, comprising adult and pediatric rheumatologists and patients. Each recommendation required ≥70% consensus among the Voting Panel. Results We present 22 recommendations and 2 ungraded position statements for GCA, and 20 recommendations and 1 ungraded position statement for TAK. These recommendations and statements address clinical questions relating to the use of diagnostic testing, including imaging, treatments, and surgical interventions in GCA and TAK. Recommendations for GCA include support for the use of glucocorticoid‐sparing immunosuppressive agents and the use of imaging to identify large vessel involvement. Recommendations for TAK include the use of nonglucocorticoid immunosuppressive agents with glucocorticoids as initial therapy. There were only 2 strong recommendations; the remaining recommendations were conditional due to the low quality of evidence available for most PICO questions. Conclusion These recommendations provide guidance regarding the evaluation and management of patients with GCA and TAK, including diagnostic strategies, use of pharmacologic agents, and surgical interventions.
2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
Langford, Carol A. , Maz, Mehrdad , Abril, Andy , Gorelik, Mark , Archer, Amy M., Conn, Doyt L. , Full, Kathy A., Grayson, Peter C. , Ibarra, Maria, Imundo, Lisa F., Kim, Susan , Rhee, Rennie L. , Stone, John H. , Sule, Sangeeta , Vitobaldi, Omar I., Warner, Ann, Byram, Kevin , Dua, Anisha B. , Husainat, Nedaa , James, Karen , Kalot, Mohamad A. , Lin, Yih Chang, Springer, Jason , Turgunbaev, Marat, Villa‐Forte, Alexandra, Turner, Amy S. , Maz, Mehrdad , Conn, Doyt L , Grayson, Peter C , Merkel, Peter A , Rhee, Rennie L , Stone, John H , Sule, Sangeeta , Husainat, Nedaa M , Kalot, Mohamad A , Springer, Jason M , Turner, Amy S , Mustafa, Reem A , Dua, Anisha B , Chung, Sharon A. , Guyatt, Gordon , Merkel, Peter A. , Seo, Philip , Sundel, Robert P. , Warner, Ann

Mayo Clinic

Arthritis & Rheumatology | July 8, 2021 | Volume: 73 | Issue: 8 | Pages: 1366-1383

10.1002/art.41773 | PMID 34235894 Get It

Objective To provide evidence‐based recommendations and expert guidance for the management of antineutrophil cytoplasmic antibody–associated vasculitis (AAV), including granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). Methods Clinical questions regarding the treatment and management of AAV were developed in the population, intervention, comparator, and outcome (PICO) format (47 for GPA/MPA, 34 for EGPA). Systematic literature reviews were conducted for each PICO question. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to assess the quality of evidence and formulate recommendations. Each recommendation required ≥70% consensus among the Voting Panel. Results We present 26 recommendations and 5 ungraded position statements for GPA/MPA, and 15 recommendations and 5 ungraded position statements for EGPA. This guideline provides recommendations for remission induction and maintenance therapy as well as adjunctive treatment strategies in GPA, MPA, and EGPA. These recommendations include the use of rituximab for remission induction and maintenance in severe GPA and MPA and the use of mepolizumab in nonsevere EGPA. All recommendations are conditional due in part to the lack of multiple randomized controlled trials and/or low‐quality evidence supporting the recommendations. Conclusion This guideline presents the first recommendations endorsed by the American College of Rheumatology and the Vasculitis Foundation for the management of AAV and provides guidance to health care professionals on how to treat these diseases.
Lactoferrin Supplementation For Taste And Smell Abnormalities Among Patients Receiving Cancer Chemotherapy
Lesser, Glenn J. , Irby, Megan B. , Taylor, Richard J. , Case, Douglas, Wang, Aili , Dietrich, Andrea, Duncan, Susan E. , Taylor, Richard, Snavely, Anna C.

Mayo Clinic

No container title available | July 7, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-603866/v1 Get It

Abstract Purpose: Taste and smell abnormalities (TSA) are common in patients receiving chemotherapy and may lead to altered nutritional intake, treatment withdrawal, and impaired quality of life. Lipid peroxidation in the oral cavity is one cause of TSA. Lactoferrin (LFN), an iron-binding salivary protein, reduces production of lipid oxidation byproducts and has been shown to reduce perception of unpleasant flavors. To assess the feasibility of LFN as a treatment for TSA, we conducted pilot investigations among patients with cancer who self-reported TSA following onset of chemotherapy. The primary objective was to assess change in subjective taste and smell perception from baseline to completion of 30-days of LFN supplementation.Methods: Patients were treated with 750mg LFN daily for 30 days and followed for an additional 30 days without LFN. TSA was measured via the taste and smell questionnaire (TSQ) including taste (score 0-10), smell (score 0-6), and composite scores (0-16, 0=no TSA) at baseline, day 30, and day 60.Results: 26 patients enrolled; 19 remained on study at day 30 and 17 at day 60. Baseline mean TSQ scores were 6.5 (taste), 3.1 (smell) and 9.6 (composite). By day 30, mean composite TSQ score improved by 1.7 (p=0.018); taste and smell improved by 0.6 (p=.062) and 1.1 (p=.042) respectively. From baseline to day 60, mean composite TSQ score improved by 3.8 (p<.0001); taste and smell improved by 1.9 (p=.001) and 1.8 (p=.003). Conclusions: Further evaluation of LFN is warranted to determine its value for improving self-reported TSA among patients receiving chemotherapy.
Abstract 6: Relationship between Center-Volume and Complication Rates in the Carotid Revascularization Endarterectomy versus Stenting Trial
Gonzales, Nicole R. , Garcia, Lawrence A., Clair, Daniel G. , Barr, John D. , Orlow, Steven, Tom, MeeLee , Hughes, Susan , Longbottom, Mary, Sheffet, Alice J., Voeks, Jenifer H. , Brott, Thomas G.

Mayo Clinic

Stroke | July 3, 2021 | Volume: 43 | Issue: suppl_1 | Pages: No page available

10.1161/str.43.suppl_1.a6 Get It

Background There is evidence that center-volume of cases affects outcomes for both carotid endarterectomy (CEA) and stenting (CAS). We sought to evaluate the effect of center-volume by site on complication rates in the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST). Methods In CREST, the primary composite endpoint was any stroke, myocardial infarction, or death within 30 days or ipsilateral stroke in follow-up. Certification was achieved by 477 surgeons performing more than 12 procedures per year with complication rates less than 3% for asymptomatic patients and less than 5% for symptomatic patients; 224 interventionists were certified after a rigorous training and credentialing process that included a lead-in registry. CREST centers were divided into tertiles based on the number of patients enrolled into the study, with Group 1 composed of 82 sites each enrolling <25 patients, Group 2 with 24 sites enrolling 25-51 patients and Group 3 with 10 sites enrolling >51 patients. Differences in periprocedural event rates for the primary composite endpoint and its components were compared using logistic regression adjusting for age, sex, and symptomatic status within site-volume level. Results The safety of CAS and CEA did not vary by site-volume during the periprocedural period as indicated by occurrence of the primary endpoint (p=0.54) or by stroke and death (p=0.87). Conclusion Complication rates (as indicated by the primary endpoint and its components) were low in CREST and were not associated with center-volume. The data are consistent with the value of rigorous training and credentialing in trials evaluating endovascular devices and surgical procedures; because of ongoing entry of new interventionalists and surgeons into CREST, operator experience independent of center-volume cannot be addressed.
Abstract 3063: Nitroglycerin Treatment Attenuates APP and BACE1 Protein Levels In Cerebral Microcirculation
Austin, Susan A., Katušić, Zvonimir S.

Mayo Clinic

Stroke | July 3, 2021 | Volume: 43 | Issue: suppl_1 | Pages: No page available

10.1161/str.43.suppl_1.a3063 Get It

Several cardiovascular risk factors are associated with an increased incidence of Alzheimer’s disease (AD); however, the mechanistic link is unknown. A common feature of cardiovascular risk factors is endothelial dysfunction, specifically, loss of bioavailability of endothelial nitric oxide (NO). Recently, we demonstrated that loss of endothelial NO led to increased protein levels of amyloid precursor protein (APP), β-site APP cleaving enzyme 1 (BACE1) and beta amyloid (Aβ) peptide. APP, the parent protein, when sequentially cleaved by BACE1 and γ-secretase generates amyloidogenic, Aβ, the primary component of AD plaques. Our data was the first to demonstrate a possible mechanism linking endothelial dysfunction, via loss of endothelial NO, with the upregulation of important AD related proteins in the cerebral microvasculature. Therefore, we sought to determine if supplementation of cultured human brain microvascular endothelial cells with NO, by utilizing the NO donor, DETA NONOate, would attenuate APP and BACE1 protein. DETA NONOate, 10 -8 to 10 -6 M, reduced expression of APP and BACE1 as compared to untreated control cells (n=3). To test the effects of NO supplementation in vivo, we treated endothelial nitric oxide synthase deficient (eNOS -/- ) mice with 30 mg/kg nitroglycerine b.i.d. or vehicle via subcutaneous injections for 3 days. No difference was observed in blood pressure between animals treated with vehicle (n=7) or nitroglycerine (n=6) (P>0.05) or before and after nitroglycerine treatment (n=6, P>0.05). As expected, cerebral microvessles of eNOS -/- animals treated with nitroglycerine displayed increased levels of cGMP as compared to vehicle (n=7-8; P<0.05). Moreover, APP and BACE1 protein levels were statistically lower in cerebral microvessels from eNOS -/- mice treated with nitroglycerine as compared to vehicle treated (n=6-7, APP, P<0.05; BACE1, P<0.05). These data indicate that supplementation with NO is able to suppress APP and BACE1 levels in the cerebrovascular endothelium. Our findings suggest that preservation of NO/cGMP signaling may be an important therapeutic target in preventing and treating mild cognitive impairment as well as AD.